Prior to joining Mylan, Glinka served as chief executive officer for the
Glinka said, "I have been following Mylan closely for some time and believe its massive global scale, vertical integration, broad product portfolio and unwavering commitment to quality are true differentiators in the highly competitive and diverse European market. I look forward to working with Mylan's global and regional leaders to continue to maximize the power of the Mylan platform across the region and further solidify Mylan's leadership positions in key markets. I also look forward to leveraging my expertise, particularly in the exciting Central and Eastern European markets, to further expand Mylan's footprint."
Prior to leading Polpharma, Glinka was a managing director at Spectra Services, where he oversaw a number of acquisitions and restructurings, including the acquisition and integration of Akrihin into
Glinka has served as member of the supervisory boards of Medana Pharma, OAO Akrihin (president of the board), Chimpharm, Polfa Lublin (president of the board), Herbapol Lublin (vice president of the board), ZT Kruszwica and Spectra Investments. He received his degree from the
This press release includes statements that constitute "forward-looking statements," including with regard to the company's future growth and performance. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the impacts of competition; changes in economic and financial conditions of the company's business; the ability to attract and retain key personnel; uncertainties and matters beyond the control of management; and the other risks detailed in the company's filings with the
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
News Provided by Acquire Media